SAB Biotherapeutics, Inc. (SABS)
 NASDAQ: SABS · Real-Time Price · USD
 3.250
 0.00 (0.00%)
  At close: Nov 3, 2025, 4:00 PM EST
3.240
 -0.010 (-0.31%)
  After-hours: Nov 3, 2025, 6:03 PM EST
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $114.70K in the twelve months ending June 30, 2025, down -95.87% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.
Revenue (ttm) 
 $114.70K
Revenue Growth 
 -95.87%
P/S Ratio 
 263.07
Revenue / Employee 
 $1,821
Employees 
 63
Market Cap 
33.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% | 
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% | 
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% | 
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% | 
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
SABS News
- 6 weeks ago - SAB BIO Highlights Data in Multiple Presentations at EASD - GlobeNewsWire
 - 2 months ago - SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - GlobeNewsWire
 - 3 months ago - SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewsWire
 - 3 months ago - SAB BIO Announces Oversubscribed $175 Million Private Placement - GlobeNewsWire
 - 6 months ago - SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewsWire
 - 7 months ago - SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewsWire
 - 9 months ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
 - 9 months ago - Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga